Autoinflammatory & rare systemic diseases

Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies

Ann Rheum DisPublished Cohort study

Authors' conclusion

Cytokine-directed therapies alone do not alter the risk of haematologic disease progression or significantly reduce glucocorticoid exposure in VEXAS.

Study context

Population
Patients with VEXAS syndrome (81.7% with anti-IL6R or Janus kinase inhibitors (JAKi) exposure)median follow-up 4.8 years
Participants
71 patients
Exposure
Event-free survival by UBA1 genotype and CHVAF≥10%; GC exposure and outcomes in relation to anti-IL6R or JAKi initiation
Outcome
Event-free survival:
  • Transfusion dependence
  • Haematopoietic stem cell transplantation
  • Death
Methodological detailsprospective follow-up for events, retrospective assessment of laboratory results, GC exposure and clinical measures
  • Prospective follow-up for events
  • Retrospective assessment of laboratory results, GC exposure and clinical measures

Main finding

As reported in the abstract

Event-free survival:
  • Events: transfusion dependence
  • HSCT
  • Death
By genotype and CHVAF≥10%
Each group vs p.M41LHR for event (transfusion dependence, HSCT or death) (95% CI)
p.M41V
5.7(1.5–20.4)
p.M41L/T with CHVAF≥10%
5.7(1.6–20.8)

Observational data: associations, not effects.

Further findings

Anaemia, elevated C-reactive protein (CRP) and monocytopenia

p.M41V genotype had the highest risk

Mean GC dose · median follow-up 4.8 (IQR 3.0, 8.1) years

Mean GC dose >15 mg/day prednisone regardless of variant or disease duration

Clinical remission on ≤10 mg/day prednisone at prospective visits

Proportion of visits
2.7%

Steroid exposure after anti-IL6R or JAKi · 1 year post-treatment

No clinically meaningful reduction (<5 mg/day difference)

Progression of anaemia after anti-IL6R and JAKi

No attenuation observed

Original publication

Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies. Ann Rheum Dis. Published 27 June 2025. doi:10.1016/j.ard.2025.05.021

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.